Pds Biotechnology Corp (PDSB) Stock Price, Quote & News

Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T c...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 208 3343

Website: www.pdsbiotech.com

Address:

303A College Road East, Princeton, United States

Whyleb111 Sep. 12 at 5:48 PM

$PDSB looks like mostly buys today, but stock is down. Odd.

0 · Reply

Test2025 Sep. 12 at 4:43 PM

$PDSB dead and forgotten

0 · Reply

billymike Sep. 11 at 6:08 PM

$PDSB loading boat yesterday wasnt a fluke IMO

1 · Reply

Mr_Charlie Sep. 11 at 5:55 PM

$PDSB the worst performing stock in my watchlist. Big expectetions without interested investors. Amazing.

0 · Reply

Mr_Charlie Sep. 11 at 2:43 PM

$PDSB this stuff is way too cheap for a company that has a platform with huge potential. Something very strange is going on.

1 · Reply

billymike Sep. 11 at 1:50 PM

$PDSB its about time a partnership was announced

0 · Reply

billymike Sep. 11 at 12:53 PM

$PDSB no volume after the need to own it at close?

1 · Reply

Mr_Charlie Sep. 11 at 9:53 AM

$PDSB I am waiting for some kind of news before market opens today.

0 · Reply

billymike Sep. 10 at 7:58 PM

$PDSB someone always knows something

0 · Reply

Mr_Charlie Sep. 10 at 7:01 PM

$PDSB some news of a partnership today after session would be great.

0 · Reply

PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 8:30 AM EDT - 18 days ago

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

Aug 13, 2025, 10:08 AM EDT - 4 weeks ago

PDS Biotechnology Corporation (PDSB) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:00 AM EDT - 4 weeks ago

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

Aug 6, 2025, 8:00 AM EDT - 5 weeks ago

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

Jul 10, 2025, 8:00 AM EDT - 2 months ago

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

Jun 9, 2025, 8:00 AM EDT - 3 months ago

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Jun 2, 2025, 8:00 AM EDT - 3 months ago

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025, 5:26 PM EDT - 4 months ago

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 20, 2025, 8:00 AM EDT - 4 months ago

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

May 14, 2025, 12:57 PM EDT - 4 months ago

PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:30 AM EDT - 4 months ago

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

May 9, 2025, 4:05 PM EDT - 4 months ago

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 8:00 AM EDT - 4 months ago

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

May 7, 2025, 8:00 AM EDT - 4 months ago

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

Apr 23, 2025, 10:16 AM EDT - 5 months ago

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 16, 2025, 8:00 AM EDT - 5 months ago

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 5 months ago

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 27, 2025, 10:35 AM EDT - 6 months ago

PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 7:30 AM EDT - 6 months ago

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Mar 25, 2025, 8:00 AM EDT - 6 months ago

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

Mar 18, 2025, 8:00 AM EDT - 6 months ago

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

Mar 13, 2025, 8:00 AM EDT - 6 months ago

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

Mar 11, 2025, 8:00 AM EDT - 6 months ago

PDS Biotech Leadership to Participate in March Conferences

Mar 7, 2025, 8:45 AM EST - 6 months ago

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

Feb 27, 2025, 8:00 AM EST - 7 months ago

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 26, 2025, 8:00 AM EST - 7 months ago

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

Feb 24, 2025, 8:00 AM EST - 7 months ago

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Feb 20, 2025, 8:00 AM EST - 7 months ago

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

Dec 3, 2024, 8:00 AM EST - 10 months ago

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

Nov 14, 2024, 11:18 AM EST - 10 months ago

PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 8:00 AM EST - 11 months ago

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

Oct 2, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

Sep 23, 2024, 10:39 AM EDT - 1 year ago

PDS Biotechnology: Continuing The Holding Pattern

Sep 9, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

Sep 3, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 7, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

Aug 2, 2024, 9:12 AM EDT - 1 year ago

PDS Biotechnology Corporation (PDSB) Clinical Program Update Conference Call (Transcript)

Aug 1, 2024, 7:45 AM EDT - 1 year ago

PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

Jul 31, 2024, 4:01 PM EDT - 1 year ago

PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time

May 15, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results

May 9, 2024, 5:46 PM EDT - 1 year ago

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

May 7, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024

May 3, 2024, 8:00 AM EDT - 1 year ago

PDS Biotechnology Announces Details of Virtual KOL Event

May 2, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Appoints Stephan Toutain as Chief Operating Officer

Apr 23, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

Mar 27, 2024, 12:17 PM EDT - 1 year ago

PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 7:30 AM EDT - 1 year ago

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

Mar 20, 2024, 8:00 AM EDT - 1 year ago

PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results

Mar 13, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

Whyleb111 Sep. 12 at 5:48 PM

$PDSB looks like mostly buys today, but stock is down. Odd.

0 · Reply

Test2025 Sep. 12 at 4:43 PM

$PDSB dead and forgotten

0 · Reply

billymike Sep. 11 at 6:08 PM

$PDSB loading boat yesterday wasnt a fluke IMO

1 · Reply

Mr_Charlie Sep. 11 at 5:55 PM

$PDSB the worst performing stock in my watchlist. Big expectetions without interested investors. Amazing.

0 · Reply

Mr_Charlie Sep. 11 at 2:43 PM

$PDSB this stuff is way too cheap for a company that has a platform with huge potential. Something very strange is going on.

1 · Reply

billymike Sep. 11 at 1:50 PM

$PDSB its about time a partnership was announced

0 · Reply

billymike Sep. 11 at 12:53 PM

$PDSB no volume after the need to own it at close?

1 · Reply

Mr_Charlie Sep. 11 at 9:53 AM

$PDSB I am waiting for some kind of news before market opens today.

0 · Reply

billymike Sep. 10 at 7:58 PM

$PDSB someone always knows something

0 · Reply

Mr_Charlie Sep. 10 at 7:01 PM

$PDSB some news of a partnership today after session would be great.

0 · Reply

Mr_Charlie Sep. 10 at 6:18 PM

$PDSB any sign of such deep pocket investor? no way

0 · Reply

EddieH2020 Sep. 10 at 4:37 PM

$PDSB I nominate Pharmdca to speak to the CEO again

0 · Reply

Fearless_Contrarian Sep. 10 at 3:49 PM

$PDSB We need activist investor with deep pockets.

0 · Reply

Ontherag Sep. 9 at 6:03 PM

$PDSB Nobody believes mOS 39.3

1 · Reply

Idvst8 Sep. 9 at 3:35 PM

$PDSB - Man this has been decimated. Catalysts on the Horizon ?>????? Need to DD again. Been a few years.

0 · Reply

Mr_Charlie Sep. 9 at 12:40 PM

$PDSB run???? Only if it is bought, no other way.

0 · Reply

EddieH2020 Sep. 9 at 12:28 PM

$PDSB That makes no sense lol

0 · Reply

technicalls Sep. 9 at 7:41 AM

$PDSB looks ready to run

0 · Reply

Ontherag Sep. 8 at 5:40 PM

$PDSB Frank not presenting at HC, only meetings, lfg, we need something soon

1 · Reply

Ontherag Sep. 7 at 12:29 AM

$PDSB This is probably just stupid coincidence, but Frank filed the employee stock options for c-suite on the same day keytruda was approved based on keynote-689. On June 12, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for adults with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) Seems kinda weird

0 · Reply

Ontherag Sep. 5 at 6:42 PM

$PDSB Keynote-689 was huge for MRK. Gotta think they would want to combine with Pds0101 and continue to help earlier stage hnscc, especially in hpv16+ while monitoring ctDNA. Frank also mentioned this phase3 was viable, but on the latest deck, did not call it out. 🤔 Still “hoping” for that partnership.

1 · Reply

Mr_Charlie Sep. 5 at 2:04 PM

$PDSB 11000 shares traded in 30min, how exciting!!

1 · Reply

Market Cap	57.84M
Revenue (ttm)	0.00
Net Income (ttm)	-37.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.81

Volume	384,800
Avg Vol	486,726
Day's Range	N/A - N/A
Shares Out	47.03M
Stochastic %K	28%
Beta	1.15
Analysts	Strong Sell
Price Target	$7.50